Loading stock data…
$1.32
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
Equillium, Inc. in the Healthcare sector is trading at $1.32 with a market capitalization of $84M. Wall Street consensus targets $8.56 (9 analysts), implying a +548.1% move over the next 12 months. The stock is currently 63% below its 52-week high of $3.54, remaining 36.5% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.16M↑ | -$5.61M↓ | -$3.96M↑ | -$4.58M↑ | -$6.23M |
| Net Income | -$4.69M↑ | -$5.31M↓ | -$3.77M↑ | -$4.23M↑ | -$5.74M |
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinica...